EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment

Eyepoint Pharma ((EYPT)) announced an update on their ongoing clinical study.

EyePoint Pharmaceuticals is conducting a Phase 3/4 clinical study titled ‘A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract.’ The study aims to assess the safety of DEXYCU, a dexamethasone intraocular suspension, in treating inflammation after ocular surgery in children with cataracts, a significant concern in pediatric ophthalmology.

The study tests two interventions: DEXYCU, an experimental single injection of dexamethasone, and Prednisolone Acetate Ophthalmic, an active comparator administered topically four times daily for 28 days. The goal is to determine the safety and efficacy of DEXYCU compared to the standard treatment.

This interventional study uses a randomized, parallel design without masking, focusing on treatment as its primary purpose. Participants are randomly assigned to either the experimental or control group to compare outcomes effectively.

The study began on December 13, 2021, and is currently recruiting participants. The last update was submitted on April 1, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s timeline and ensuring transparency in its development.

The outcome of this study could significantly impact EyePoint Pharmaceuticals’ market position, potentially boosting investor confidence if results are favorable. The pharmaceutical industry closely watches such developments, as successful trials can lead to increased stock performance and competitive advantages.

The study is ongoing, with further details available on the ClinicalTrials portal.